Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Enceph…

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
Fierce Biotech

Bright Minds shines with phase 2 win for anti-seizure serotonin receptor activator

Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...

Bright Minds gains on mid-stage trial win for lead asset

Bright Minds Biosciences (DRUG) added ~10% in the premarket on Tuesday after the company said that its lead asset, BMB-101, ...
TipRanks on MSN

Bright Minds announces results from phase 2 BREAKTHROUGH trial of BMB-101

Biosciences announced positive and significant topline results from its Phase 2 BREAKTHROUGH clinical trial evaluating ...
The Scientist

Researchers Homing In On Mechanisms Of Encephalopathic Diseases

Encephalopathic Diseases One of the great biomedical quests of the last 20 years surrounds a handful of rare and mysterious brain diseases that affect humans and a small group of other mammals. An ...